Assessment of Effect of Rapastinel on Driving Performance

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04590495` - The Effects of Cannabidiol on the Driving Ability of Healthy Adults	Phase 2

NCT number	NCT03814733
Study type	Interventional
Source	Naurex, Inc, an affiliate of Allergan plc
Contact
Status	Completed
Phase	Phase 1
Start date	November 5, 2018
Completion date	April 3, 2019

Assessment of Effect of Rapastinel on Driving Performance

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms